Literature DB >> 21737763

Glycemic control patterns and kidney disease progression among primary care patients with diabetes mellitus.

Doyle M Cummings1, Lars C Larsen, Lisa Doherty, C Suzanne Lea, Don Holbert.   

Abstract

BACKGROUND: Reducing glycosylated hemoglobin (HbA1c) to near or less than 7% in patients with diabetes is associated with diminished microvascular complications, but this level is not consistently achieved. The purpose of this study was to examine the relationship between fluctuations in HbA1c and changes in estimated glomerular filtration rate (eGFR) and estimated stage of chronic kidney disease (CKD) in an academic primary care practice.
METHODS: We analyzed data from 791 diabetic primary care patients (25% white; 75% African American) enrolled between 1998 to 2002 and followed through 2008 (mean follow-up, 7.6 ± 1.9 years). We calculated baseline and final follow-up eGFR using the Modification of Diet in Renal Disease equation. We examined the relationship between fluctuations in HbA1c and changes in eGFR and stage of CKD using multivariable linear and logistic regression models that controlled for demographic and clinical variables associated with CKD progression.
RESULTS: From baseline to follow-up, mean eGFR in African Americans declined to a greater extent and more rapidly than in whites. Age, mean systolic blood pressure, initial HbA1c, initial eGFR, and number of HbA1c values (all P<.01) were significant predictors of change in eGFR. Among HbA1c fluctuation measures, the strongest predictor of change in eGFR was the proportion of HbA1c values >7% (P=.02); however, this contributed little to explaining model variance.
CONCLUSION: These data suggest that traditional demographic and clinical risk factors remain significantly associated with changes in eGFR and that the pattern of variability in HbA1c is only modestly important in contributing to changes in eGFR among African-American and white diabetic patients in primary care.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21737763     DOI: 10.3122/jabfm.2011.04.100186

Source DB:  PubMed          Journal:  J Am Board Fam Med        ISSN: 1557-2625            Impact factor:   2.657


  6 in total

1.  Influence of HbA1c on short-term blood pressure variability in type 2 diabetic patients with diabetic nephropathy.

Authors:  Fang Liu; Min Wu; Yan-huan Feng; Hui Zhong; Tian-lei Cui; You-qun Huang; Ya-ping Liang; Yong-shu Diao; Li Zang; Ling Li; Jing Zang; Hong-yu Qiu; Song-min Huang; Ping Fu
Journal:  J Zhejiang Univ Sci B       Date:  2013-11       Impact factor: 3.066

2.  Long-term evolution of renal function in patients with type 2 diabetes mellitus: a registry-based retrospective cohort study.

Authors:  Geert Goderis; Gijs Van Pottelbergh; Carla Truyers; Viviane Van Casteren; Etienne De Clercq; Carine Van Den Broeke; Frank Buntinx
Journal:  BMJ Open       Date:  2013-12-30       Impact factor: 2.692

3.  The impact of the quality of care and other factors on progression of chronic kidney disease in Thai patients with Type 2 Diabetes Mellitus: A nationwide cohort study.

Authors:  Paithoon Sonthon; Supannee Promthet; Siribha Changsirikulchai; Ram Rangsin; Bandit Thinkhamrop; Suthee Rattanamongkolgul; Cameron P Hurst
Journal:  PLoS One       Date:  2017-07-28       Impact factor: 3.240

4.  A Cross-sectional Retrospective Analysis of Glycemic Burden and Nephropathy in an Indian Population and Formulation of a New Plan Using eGFR/HbA1c Grid Formation.

Authors:  Sayak Roy; Kingshuk Bhattacharjee
Journal:  Cureus       Date:  2019-08-13

5.  Access to CKD Care in Rural Communities of India: a qualitative study exploring the barriers and potential facilitators.

Authors:  Tazeen Hasan Jafar; Chandrika Ramakrishnan; Oommen John; Abha Tewari; Benjamin Cobb; Helena Legido-Quigley; Yoon Sungwon; Vivekanand Jha
Journal:  BMC Nephrol       Date:  2020-01-29       Impact factor: 2.388

6.  A systematic review of statistical methodology used to evaluate progression of chronic kidney disease using electronic healthcare records.

Authors:  Faye Cleary; David Prieto-Merino; Dorothea Nitsch
Journal:  PLoS One       Date:  2022-07-29       Impact factor: 3.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.